[Use of recombinant alpha2-interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia].
The authors present results of chronic myeloid leukemia (CML) treatment with recombinant and leukocytic interferon in monotherapy and in combination with myelosan. The best responses (72% of complete hematological remissions) were obtained in patients pretreated with myelosan (one course of 1-1.5 months) in combination with natural antioxidants.